证券日报网讯 7月29日，君实生物在互动平台回答投资者提问时表示，JS207（PD-1/VEGF双抗）正处于II期临床研究阶段，正在多个瘤种中开展与化疗、单抗、ADC等不同药物的联合探索。JS207与JS212（EGFR/HER3 ADC）联合用药的II期临床试验正在进行。未来公司计划基于前期临床数据，将JS207快速推进至关键注册临床阶段。（文章来源：证券日报）
Source Link证券日报网讯 7月29日，君实生物在互动平台回答投资者提问时表示，JS207（PD-1/VEGF双抗）正处于II期临床研究阶段，正在多个瘤种中开展与化疗、单抗、ADC等不同药物的联合探索。JS207与JS212（EGFR/HER3 ADC）联合用药的II期临床试验正在进行。未来公司计划基于前期临床数据，将JS207快速推进至关键注册临床阶段。（文章来源：证券日报）
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.